Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis

References

• Mitchell DM, Spits PW, Young DY, et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706–14.
   PubMed Web of Science ®Google Scholar
• Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987;30:507–12.
   PubMed Web of Science ®Google Scholar
• ACR Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713–22.
   Google Scholar
• Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Ftheumatol 1989;16:585–91.
   Google Scholar
• O'Dell JR. The treatment of rheumatoid arthritis in 1995: results of a survey [abstract]. Arthritis Rheum 1995;38: Suppl S366.
   Google Scholar
• Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992;35:138–45.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992;35:129–37.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1995;38:1173–4.
   Google Scholar
• Yoshida H, Fujisawa H, Abe C, et al. Effect of MS-932 (4-acetylaminophenylacetic acid) on articular lesions in MRL/1 mice. Int J Immunother 1990;6:261–4.
   Google Scholar
• Nakagawa Y, Ogawa T, Umezu K, et al. Characterization of sup-pressor cells activated by 4-acetylaminophenylacetic acid (MS-932) on delayed-type hypersensitivity. Int J Immunother 1990;6:149–56.
   Google Scholar
• Nakagawa Y, Ogawa T, Kobayashi M, et al. Immunophar-macological studies of 4-acetylaminophenylacetic acid (MS-932). Int J Immunother 1990;6:131–40.
   Google Scholar
• Nishimura T, Abe C, Hirose S, et al. Effect of MS-932 (4-acetylaminophenylacetic acid) on delayed-type hypersensitivity reaction induced by the influenza virus A/Kumamoto haemag-glutinin in cyclophosphamide-treated mice. Int J Immunophar-macol 1998;4:73–7.
   Google Scholar
• Nakagawa Y, Ogawa T, Umezu K, et al. Suppressive effect of 4-acetylaminophenylacetic acid (MS-932) on delayed-type hypersen-sitivity in mice. Int J Immunopharmacol 1990;6:141–8.
   Google Scholar
• Fujisawa H, Nishihara T, Inaba M, et al. Suppressive effect of actarit on IgA production in mice: activation of CD4+ suppressor T cells in Peyer's patches. Int J Immunopharmacol 1990;17:611–7.
   Google Scholar
• Takeba Y, Suzuki N, Wakisaka S, et al. Effects of actarit on synovial cell function in patients with rheumatoid arthritis. J Ftheumatol 1999;26:25–33.
   Google Scholar
• Hamada A, Tsuji H, Ohnari H, et al. Combination therapy of gold and actarit for patients with active rheumatoid arthritis resisted to gold. Ftheumatology 1996;16:609–17.
   Google Scholar
• Kosakai O, Ooki M, Shito K. Combination therapy of actarit and mizoribine for the treatment of rheumatoid arthritis of early stage (2 cases report). Ftheumatology 1997;17: 554–8.
   Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American College of Ftheumatology preliminary definition of improvement in rheuma-toid arthritis. Arthritis Rheum 1995;38:727–35.
   PubMed Web of Science ®Google Scholar
• Furst DE. Optimizing combination therapy for rheumatoid arthri-tis. Ann NY Acad Sci 1993;696:285–91.
   Google Scholar
• Harris ED Jr. The rationale for combination therapy of rheuma-toid arthritis based on pathophysiology. J Ftheumatol 1996;23 Suppl 44:2–4.
   Google Scholar
• Tanaka Y, Fujii K, Hubscher S, et al. Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhe-sion by immobilizing chemokines in rheumatoid synovitis. Arthri-tis Rheum 1998;41:1365–77.
   PubMed Web of Science ®Google Scholar
• Abe M, Tanaka Y, Saito K, et al. Regulation of interleukin (IL)-1 (3 gene transcription induced by IL-1(3 in rheumatoid synovial fibroblast-like cells, Ell, transformed with simian virus 40 large T antigen. J Ftheumatol 1997;24:420–9.
   Google Scholar
• Nakatuska K, Tanaka Y, Hubscher S, et al. Rheumatoid synovial cells are stimulated by the cellular adhesion to T cells through LFA-1/ICAM-1. J Ftheumatol 1997;24:458–64.
   Google Scholar
• Koyama Y, Tanaka Y, Saito K, et al. Cross-linking of intercellular adhesion molecule-1 (CD54) induces AP-1 activation and interleukin-lp transcription. J Immunol 1997;157:5097–103.
   Google Scholar
• Brook AJ, Corbett M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis 1977;36:71-3m.
   Google Scholar
• Furst DE. Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis. J Ftheumatol 1996;23 Suppl 44:86–90.
   Google Scholar
• Joseph MC, John HK. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330:1368–75.
   Google Scholar
• Williams HJ, Willkens FtF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985;28:721–30.
   PubMed Web of Science ®Google Scholar
• Furst DE. Rational use of disease-modifying antirheumatic drugs. Drugs 1990;39:19–37.
   Google Scholar
• O'dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxy-chloroquine, or a combination of all three medications. N Engl J Med 1996;334: 1287–91.
   Google Scholar
• Yocum DE. Combination therapy with cyclosporine in rheumatoid arthritis. J Ftheumatol 1996;23 Suppl 44:75–7.
   Google Scholar
• Constantin A, Lescoulie PL, Lambert N, et al. Anti inflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1998;41:48–57.
   PubMed Web of Science ®Google Scholar
• Shiokawa Y, Shichikawa K, Nobunaga T, et al. Clinical study of a new anti-rheumatic drug, MS-932, on rheumatoid arthritis: double-blind comparative study with placebo. Ftinshoiyaku 1991;7 Suppl 2:113–47.
   Google Scholar
• Okano Y, Akizuki M, Kondo H, et al. A new approach assessing rheumatoid arthritis (RA) disease activity using the American College of Ftheumatology core set of disease activity measures for RA trials. Ryumachi 1997;37:467–75.
   Google Scholar